A kind of (r)-omega-transaminase mutant and its application

A mutant, transaminase technology, applied in the application, transferase, enzyme and other directions, can solve the problem of lack of competitive advantages, and achieve the effects of high stereoselectivity, high enzyme activity and high conversion rate

Active Publication Date: 2021-10-01
ZHEJIANG UNIV OF TECH +2
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] In the case that the current asymmetric synthesis of sitagliptin technology is monopolized by Merck and Codexis, the substrate concentration of other technical routes for the preparation of sitagliptin by (R)-ω-TA still does not have a competitive advantage

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of (r)-omega-transaminase mutant and its application
  • A kind of (r)-omega-transaminase mutant and its application
  • A kind of (r)-omega-transaminase mutant and its application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] Example 1 Screening, determination of stereoselectivity and precise determination of enzyme activity of novel ω-TA

[0033] 1. Enzyme source and gene synthesis

[0034] Using the amino acid sequence of the commercial enzyme (R)-ω-TA 117 as a template, three ω-TA strains were obtained by gene mining from the NCBI database, namely Aspergillus terreus TA (AtTA, GenBank No. XP_001209325.1), Mycolicibacterium wolinskyi TA (MwTA , GenBank accession WP_067853383) and Aspergillus parasiticus TA (ApTA, GenBank accession KJK66446).

[0035] The sequence identity rates of the above three enzymes with (R)-ω-TA 117 were 38.14%, 48.97% and 37.9%, respectively. Codon optimization was carried out according to the codon preference of E.coli, and three strains of enzymes were synthesized by the method of whole gene synthesis, 6×His-tag tags were added at the end of the nucleic acid sequence, and restriction sites Xho I and Nco I were added at both ends, The gene was cloned into the cor...

Embodiment 2

[0058] Example 2 Construction and screening of AtTA single point mutants

[0059] 1. Mutant construction

[0060] The novel (R)-ω-TA screened was subjected to single-point mutation, and mutation primers were designed according to the nucleotide sequence of AtTA (shown as SEQ ID NO.2), and the recombinant vector pET28b / AtTA was used as the recombinant vector by using rapid PCR technology. Template, introduce a single mutation at position 182 of the amino acid sequence of AtTA, and the primers are:

[0061] Forward primer: TGAAAAAT NNK CAGTGGGGTGATCTGGTGC (the underline is the mutated base, as shown in SEQ ID NO.4)

[0062] Reverse primer: CCCCACTG MNN ATTTTTCACAGTCGGGTCA (the underline is the mutant base, as shown in SEQ ID NO.5)

[0063] PCR reaction system: 2×Phanta Max Buffer (containing Mg 2+ ) 25μL, dNTPs 10mM, forward primer 2μL, reverse primer 2μL, template DNA 1μL, Phanta Max Super-Fidelity DNA Polymerase 50U, add ddH 2 0 to 50 μL.

[0064] The PCR amplificatio...

Embodiment 3

[0078] Example 3 Construction and screening of AtTA two-site mutants

[0079] The single mutant AtTA constructed according to Example 2 1 Sequence design of mutation primers for site-directed mutagenesis, using rapid PCR technology to recombinant vector pET28b / AtTA 1 as the template, the AtTA 1 A single mutation is introduced at position 79 of the amino acid sequence, and the primers are:

[0080] Forward primer: ACATTACG NNK CTGGAGGCTAGCTGCACCA (the underline is the mutant base, as shown in SEQ ID NO.6)

[0081] Reverse primer: GCCTCCAG MNN CGTAATGTGGTCATCCAGA (the underline is the mutant base, as shown in SEQ ID NO.7)

[0082] The PCR reaction system is the same as the "construction of mutants" in Part 1 of Example 2.

[0083] The PCR amplification conditions were: 95°C for 3min; (95°C for 15s, 50°C for 15s, 63°C for 6.5min) 30 cycles; 72°C for 5min.

[0084] The PCR product was transformed into E.coli BL21(DE3) competent cells, and a single clone was picked in LB l...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention discloses a mutant of (R)-ω-transaminase and its application. The mutant is composed of leucine at position 182, arginine at position 79, arginine at position 51 in the amino acid sequence shown in SEQ ID NO.1. Glutamine at position 1, valine at position 149, leucine at position 235 and glycine at position 216 were obtained through multiple point mutations. The present invention screens novel (R)-ω-TA enzymes through gene mining technology, and carries out molecular transformation through protein engineering technology to obtain (R)-ω-TA enzymes with high enzyme activity, high substrate tolerance and high stereoselectivity ‑TA mutant catalyst capable of biocatalyzing the precursor ketone analog 1‑(3‑oxypyrrolidin‑1‑yl)‑4‑(2,4,5‑trifluorophenyl)‑1,3‑ Synthesis of sitagliptin intermediate (R)-1-[3-amino-4-(2,4,5-trifluorophenyl) butyryl]pyrrole-3-one from diacetyl, with high conversion rate, It can reach up to 95.4%, which is a milestone for breaking through the biocatalytic preparation technology of sitagliptin.

Description

technical field [0001] The present invention relates to the field of biochemical technology, in particular to a (R)-ω-transaminase mutant and its application, especially the (R)-ω-transaminase mutant in the preparation of sitagliptin intermediate (R)-1- [3-Amino-4-(2,4,5-trifluorophenyl)butyryl]pyrrol-3-one. Background technique [0002] Sitagliptin, English name sitagliptin, full name (3R)-3-amino-1-[3-(trifluoromethyl)-5,6,7,8-tetrahydro-1,2,4-triazolo [4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one, a dipeptidyl group researched and developed by Merck and Codexis Peptidase-4 (DPP-4) inhibitors, which can control blood sugar levels by protecting endogenous incretins and enhancing their effects, are a therapeutic drug with great potential for type Ⅱ diabetes. [0003] The preparation of sitagliptin is mainly an asymmetric synthesis method, usually using transaminase as a biocatalyst for biotransformation. Transaminase (TA for short, EC 2.6.1.X) is a coenzyme-ty...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): C12N9/10C12N15/54C12N15/70C12N1/21C12P41/00C12P17/10C12R1/19
CPCC07K2319/21C12N9/1096C12N15/70C12N2800/22C12P17/10C12P41/006C12Y206/01
Inventor 柳志强贾东旭彭晨李军良程峰张晓健郑裕国何人宝金逸中林娇华
Owner ZHEJIANG UNIV OF TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap